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www.embomolmed.org EM‘Tomacula’ and myelin outfoldings are striking neuropathological features of a
diverse group of inherited demyelinating neuropathies. Whereas the underlying
genetic defects are well known, the molecular mechanisms of tomacula formation
have remained obscure. We hypothesized that they are caused by uncontrolled,
excessive myelin membrane growth, a process, which is regulated in normal
development by neuregulin-1/ErbB2, PI3 Kinase signalling and ERK/MAPK signal-
ling. Here, we demonstrate by targeted disruption of Pten in Schwann cells that
hyperactivation of the endogenous PI3 Kinase pathway causes focal hypermyeli-
nation, myelin outfoldings and tomacula, even when induced in adult animals by
tamoxifen, and is associated with progressive peripheral neuropathy. Activated
AKT kinase is associated with PtdIns(3,4,5)P3 at paranodal loops and Schmidt–
Lanterman incisures. This striking myelin pathology, with features of human CMT
type 4B1 and HNPP, is dependent on AKT/mTOR signalling, as evidenced by a
significant amelioration of the pathology in mice treated with rapamycin. We
suggest that regions of non-compact myelin are under lifelong protection by PTEN
against abnormal membrane outgrowth, and that dysregulated phosphoinositide
levels play a critical role in the pathology of tomaculous neuropathies.INTRODUCTION
Inherited neuropathies, known as Charcot Marie Tooth disease
(CMT) or hereditary motor and sensory neuropathies (HMSN),
comprise a genetically heterogeneous group of neuromuscular
disorders of considerable prevalence (Skre, 1974). The main
clinical features of CMT diseases are a distally accentuated
muscle weakness and atrophy, foot deformities and sensory
deficits. While progressive loss of long axons is a common
feature, in the demyelinating forms, there is also a characteristic
slowing of nerve conduction velocity (NCV) associated withttingen, Germany
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BO Mol Med 4, 1–14primary abnormalities of the myelin architecture (Berger et al,
2006). Within the last 20 years, numerous CMT disease genes
have been identified and specific animal models have been
generated (Meyer Zu Ho¨rste & Nave, 2006; Pareyson et al, 2009;
Scherer & Wrabetz, 2008). Nonetheless, the molecular mechan-
isms that link different primary genetic defects with the final
common pathway in CMT neuropathies are poorly understood.
Several reports have identified CMT-relevant mutations in
genes encoding proteins with phosphoinositide binding
domains like dynamin 2 (Zuchner et al, 2005) and FGD4/frabin
(Delague et al, 2007; Stendel et al, 2007) and in phosphoinosi-
tide phosphatases such as the D5-phosphatase FIG4 (in CMT-4J)
that dephosphorylates PtdIns(3,5)P2 (Chow et al, 2007).
Mutations in the gene for the myotubularin-related protein-2
(MTMR2), a D3-phosphatase that dephosphorylates both
PtdIns(3)P and PtdIns(3,5)P2, underlie the autosomal recessive
form CMT-4B1 (Bolino et al, 2000; Bolis et al, 2005; Bonneick
et al, 2005; Houlden et al, 2001; Nelis et al, 2002). A similar
neuropathy, CMT-4B2, is caused by mutations in the gene for
MTMR13/Set-binding factor-2 (SBF2). While this protein is
catalytically inactive, it forms a tetrameric complex with
MTMR2, thereby strongly increasing that enzyme’s activity 2012 EMBO Molecular Medicine 1
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2(Berger et al, 2006; Bolis et al, 2007; Robinson et al, 2008;
Tersar et al, 2007). Mechanistically, it is still incompletely
understoodwhy the dysregulation of phosphoinositides, such as
PtdIns(3,5)P2, in Schwann cells perturbs myelination and
myelin sheath maintenance (Suter, 2007).
At the same time it has become clear that a diverse group
of inherited demyelinating neuropathies is associated with
extensive myelin production that manifests histologically as
myelin outfoldings or focal thickening of the myelin sheath
(‘tomacula’). This ranges from CMT-4B (see above), CMT-4H
(mutations in the FGD4/frabin gene; Delague et al, 2007; Fabrizi
et al, 2009; Stendel et al, 2007), CMT-4F (mutations in the
periaxin gene) (Gillespie et al, 2000; Takashima et al, 2002), and
CMT-1B (specific mutations in the myelin protein zero gene,
MPZ; Fabrizi et al, 2000) to hereditary neuropathy with liability
to pressure palsies (HNPP, haplo-insufficiency of PMP22;
Adlkofer et al, 1997).
We hypothesized that one candidate responsible for abnor-
mal myelin overproduction is phosphatidylinositol-3,4,5-tri-
sphosphate (PtdIns(3,4,5)P3). This signalling lipid is generated
from the pool of available PtdIns(4,5)P2 by the activity of
phosphoinositide-3-kinase (PI3K). In myelinated nerves, PI3K is
activated when axonal NRG1 type III binds to glial ErbB2/ErbB3
receptor heterodimers and PtdIns(3,4,5)P3 promotes myelina-
tion in an AKT/PKB-dependent fashion, at least in vitro (Liang
et al, 2007; Maurel & Salzer, 2000; Ogata et al, 2004; Taveggia
et al, 2005). PI3K activity is antagonized by the lipid
phosphatase PTEN (phosphatase and tensin homolog) (Stiles
et al, 2004; Suzuki et al, 2008). PTEN inhibits myelination
(Goebbels et al, 2010), specifically in conjunction with the
mammalian Disc-large homolog Dlg1 in Schwann cells (Cotter
et al, 2010).
In the present study, we characterized a novel neuropathy
model in mice and tested the hypothesis that myelin outfoldings
and tomacula result from a local loss of myelin growth control,
modelled by abnormal PtdIns(3,4,5)P3 stimulation in Schwann
cells. This was achieved by analysing a cell-specific mouse
mutant of PTEN.We show that the elevation of PI(3,4,5)P3 levels
in mutant Schwann cells is sufficient to cause myelin outfoldings
and tomacula. This pathology is prominent even when the Pten
expression is targeted in adult animals, i.e. after the completion of
myelination.We suggest that PTEN inmyelinating Schwann cells
serves to protect the mature sheath from aberrant membrane
outgrowth at paranodal loop regions and Schmidt–Lanterman
incisures, which emerge asmyelin growth zones. Amelioration of
the neuropathology by the treatment of mice with rapamycin
demonstrates an essential role of the mTOR downstream
signalling in tomacula formation, which is of possible relevance
for the development of novel therapies.RESULTS
Focal hypermyelination in the PNS of mice lacking PTEN in
Schwann cells
We have previously generated mice that lack expression of a
floxed Pten gene in oligodendrocytes and Schwann cells, 2012 EMBO Molecular Medicinefollowing expression of Cre under control of the Cnp1 gene
regulatory region (Goebbels et al, 2010). In peripheral nerves,
this recombination led to significantly increased levels of
PtdIns(3,4,5)P3 and decreased levels of PtdIns(4,5)P2, asso-
ciated with significant hypermyelination (as evidenced by
decreased g-ratios) of sciatic nerve axons smaller than 2mm in
diameter (Goebbels et al, 2010). These findings support the role
of PI3K signalling in myelination control.
Western blot analysis of sciatic nerve lysates from conditional
Ptenmutants confirmed the significant downregulation of PTEN
protein and an enhanced phosphorylation of the known PI3K
downstream target proteins AKT, mTOR and S6, but no changes
in the level of phosphorylated ERK1/2 (Fig 1A). When we
determined the degree of myelination for axons larger than 2mm
in diameter, we found a g-ratio for the Pten mutants (Ptenflox/
floxCnpCre/þ) of 0.6345 (0.0094), which is not significantly
different from controls (Ptenflox/floxCnpþ/þ; 0.6339 0.0129)
(Fig 1B). Surprisingly, we noticed that numerous axons
exhibited instead a hypermyelination of focal origin, i.e.
tomacula and myelin outfoldings (left panels in Fig 1C).
This finding is specific for the conditional Pten null mutants
and not present in heterozygous Ptenflox/þCnpCre/þ mice
(right panels in Fig 1C), implying that the complete loss of
PTEN expression is required to develop focal myelin pathology.
We quantified the onset and progression of the myelin
abnormalities (Fig 2A) by analysing Pten mutants and controls
at postnatal day (P) 12 and at 3 months of age (P90) (n¼ 3 for
each genotype and age) by comparing methylene blue-stained
semithin cross sections of sciatic nerves. Already at P12,
abnormal Schwann cell-axon units could be observed with
1.4% of the fibres affected by tomaculous pathology and
0.2% exhibiting ‘comma-shaped’ myelin outfoldings. At
P90, 6.6% of mutant fibres showed a tomaculous pathology
and 2.8% exhibited comma-shaped myelin outfoldings.
Given the frequency of tomacula in cross-sections of the
sciatic nerve, we must assume that virtually all large calibre
axons are affected somewhere along their length by focal myelin
overgrowth.
By electron microscopy (EM), myelin outfoldings in cross
sections contained no axonal structures (arrowhead in Fig 2C).
Myelin membranes were either facing away from the axon
cylinder or coiled around the axon presumably representing an
initial stage in the formation of a tomaculum (Fig 2B and C). In
more advanced forms, the excess myelin lamellae that were
folded around the axons appeared fused to the original myelin
sheath (tomaculum; Fig 2D and G). With age, complexity of the
neuropathology progressed. While some outfoldings were
orientated perpendicular to the nerve axis (termed ‘comma-
shaped’ outfoldings, Fig 2B and C), others were aligned parallel
to the axon. The latter appeared (in cross sections) as concentric
rings of myelin, adjacent to a ‘normally’ myelinated axon
(termed ‘recurrent loops’; Fig 2E). ‘Evaginating’ and also
‘invaginating’ recurrent loops (Fig 2E and F) always showed the
same number of myelin lamellae, periodicity and degree of
compaction as the myelin sheath from which they had
originated. EM images of redundant myelin also revealed axons
that were displaced, deformed or constricted (Fig 2D, F and G).EMBO Mol Med 4, 1–14 www.embomolmed.org
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Figure 1. Focal hypermyelination in PTEN mutants.
A. Westernblot analysis of sciatic nerve lysates obtained from two controls and two mutants at the age of 3 months. PTEN protein is decreased in the mutants and
P-AKT, P-mTOR and P-S6 levels are increased. In contrast the levels of phosphorylated ERK1 and ERK2 are unchanged in mutants compared to controls.
B. Scatter plot depicting g-ratios (ordinate) of 1.5 month-old mutant and age-matched control mice in relation to the axon diameter (abscissa) based on semithin
sections of sciatic nerves at comparable levels (left panel). Axons with calibres larger than 2mm in diameter show no alteration in myelin sheath thickness in
mutants when compared to controls (right panel) (n¼ 6 for mutants; n¼ 8 for controls; p¼0.9728). Error bars represent the SEM. The p value was calculated
by two-tailed Student’s t-test.
C. Left panels: light-microscopic analysis of myelin abnormalities on sciatic nerve transverse semithin-sections (500 nm) of mutants (Ptenflox/floxCnpCre/þ) and
controls (Ptenflox/floxCnpþ/þ) at the indicated ages. Mutant nerves are characterized by a progressive development of myelin abnormalities like tomacula
(arrowheads), comma-shaped myelin outfoldings (arrows) and recurrent myelin loops (asterisks). Scale bars, 20mm. Right panels: light-microscopic analysis of
sciatic nerve semithin cross-sections (500 nm) reveals no myelin pathology in heterozygous Ptenflox/þCnpCre/þ mice when compared to Ptenþ/þCnpCre/þ
controls at 1 year of age.Hence, we observed signs of axonal damage, which included
macrophage processes removing redundant myelin (Fig 2H). As
signs of perturbed axonal transport leading to axonal degenera-
tion we observed the accumulation of organelles (mainly
mitochondria) in the axoplasm (Fig 2I). More progressed forms
were characterized by irregular distribution of neurofilaments
and microtubules (Fig 2J) and Wallerian-type axonal degenera-
tion with myelin debris (Fig 2K).www.embomolmed.org EMBO Mol Med 4, 1–14Myelin abnormalities emanating from non-compacted
regions
Teased fibre preparations (osmicated, age P46) and electron
microscopic analysis of longitudinal sciatic nerve sections (P30)
revealed that myelin abnormalities predominantly originated
from paranodal regions and Schmidt–Lanterman incisures
(Fig 3A and B). These regions of non-compacted myelin are
thought to represent zones in which controlled membrane 2012 EMBO Molecular Medicine 3
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Figure 2. Quantitative and ultrastructural
analysis of abnormal axon/Schwann cell units.
A. When counted on semithin sciatic nerve cross
sections, tomacula and comma-shaped out-
foldings increased in number with age
(tomacula: 1.44 0.10% for P12 mutants and
6.55 0.07% for P90 mutants; outfoldings:
0.24 0.07% for P12 mutants and
2.76 0.25% for P90 mutants; n¼ 3 per
genotype and age). Error bars represent the
SEM. p values were calculated by two-tailed
Student’s t-test.
B–K. Ultrastructural analysis of focally redundant
myelin in mutant sciatic nerves appearing as
comma-shaped outfoldings (B, C), tomacula
(D) and recurrent loops (arrow in E). Myelin
outfoldings contain no axonal structures
(arrowhead in C). Invaginating recurrent loops
exhibit the same spacing and number of
lamellae as the myelin sheath they originate
from (inset in F). Nearly regular appearing
hypermyelination also occurs (G). Occasionally,
processes of macrophages are observed that
actively remove redundant myelin (arrow-
heads in H). Accumulation of axoplasmic
organelles (I), degeneration of microtubules
and neurofilaments (arrowhead in J), and
Wallerian-type degeneration (K) indicate dis-
turbed axonal functions. A, axon. MD, myelin
debris. Scale bars, 1mm.
4incorporation and myelin growth takes place. We therefore
asked whether the lack of PTEN would mimic abnormally
enhanced axon–glia signalling and PI3K activation in these
regions. Indeed, when p-AKT was used as an indirect sensor
of elevated PtdIns(3,4,5)P3 levels, and sections were co-
immunostained for P0 (MPZ, a marker of compact myelin)
and myelin-associated glycoprotein (MAG, a marker of non-
compacted myelin), we found a striking localization of p-AKT in
MAG-positive Schmidt–Lanterman incisures and paranodes
(Fig 4A and B). This suggests that incisures and paranodes
are regions in which PTEN normally downregulates the level of
PtdIns(3,4,5)P3 and that this signalling lipid, if experimentally
enhanced in our conditional mutants, drives a local deposition
of myelin membranes. The cell polarity proteins Par-3 and Dlg1,
which interact with PTEN via their PDZ domains (Adey et al,
2000; Feng et al, 2008), have been localized in regions of non- 2012 EMBO Molecular Medicinecompact myelin (Bolino et al, 2004; Poliak et al, 2002) and
have independently been associated with a role in myelination
(Bolis et al, 2009; Chan et al, 2006; Cotter et al, 2010). The
localization of both proteins was unchanged in Pten mutant
nerves when immunohistochemically stained in teased fibre
preparations (Fig 4C).
Reduced nerve conduction velocity and compound muscle
action potentials
To determine whether Pten conditional mutants model a human
peripheral neuropathy by clinical criteria, electrophysiology of
the sciatic nerve was performed on mice at age P43, i.e. when
clear histological signs of pathology are present. Motor NCVwas
slower in Pten mutants (17.7 3.7m/s) compared to age-
matched controls (26.7 3.8m/s). In addition we observed
markedly reduced compound muscle action potentials (CMAP)EMBO Mol Med 4, 1–14 www.embomolmed.org
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Figure 3. Myelin abnormalities preferentially
originate at regions of non-compact myelin.
A. Osmicated teased nerve fibres from 1.5 month-
old control and mutant mice. Focal myelin
thickenings preferentially originate at paranodal
regions (black arrows) and Schmidt–Lanterman
incisures (SLI) (yellow arrows). SLI are indicated
by asterisks. Note in left panel that either one or
both paranodal regions can be affected. Scale
bars, 10mm.
B. Ultrastructural appearance of exuberant myelin
growth (arrows) at paranodal regions (left panel)
and SLI (marked by asterisk in right panel). A,
axon; N, node. Scale bars, 2mm.when recorded after distal (7.4 2.7mV in mutants vs.
21.8 2.2mV in controls) and proximal stimulation
(5.3 2.4mV vs. 19.8 2.7mV) (Fig 5 and Table 1).
Rapamycin treatment ameliorates myelin abnormalities
Ablation of Pten is generally associated with the constitutive
activation of PI3K downstream effectors, including the serin-
threonine kinases AKT and mTOR. To analyse whether
inhibition of mTOR signalling in turn interferes with focal
hypermyelination we treated Pten mutants and littermate
controls with rapamycin, a specific mTOR inhibitor. The drug
was given from P13, when mutant sciatic nerves exhibited only
minor myelin pathology, to age P43, when the clinical
phenotype was more pronounced. Both rapamycin-treated
mutants and controls gained less weight in this time window
than the placebo-treated animals (weight gain of controls,
6.8 0.6 g with rapamycin, n¼ 7 vs. 9.4 0.8 g without
rapamycin, n¼ 7, p< 0.05; weight gain of mutants, 7.1 0.2 g
with rapamycin, n¼ 7 vs. 11.2 0.3 g without rapamycin, n¼ 6,
p< 0.001). This was expected and is consistent with the known
role of mTOR in growth control.
To evaluate specificity and efficiency of rapamycin-mediated
inhibition of mTOR signalling, we analysed the activity of
upstream and downstream kinases of the mTOR pathway in
Pten mutants. Because mTOR signalling activates S6 Kinase,
which phosphorylates ribosomal S6 (Saitoh et al, 2002), we
determined the level of phospho-S6 (p-S6) as an indicator of
mTOR activity. By Westernblot analyses of sciatic nerve lysates
rapamycin-treated mutants had strongly diminished p-S6 levels
compared to placebo-treated mutants, demonstrating efficient
blockage of the mTOR pathway (Fig 6A). In contrast, levels of
pAKT were elevated in sciatic nerves of both placebo- and
rapamycin-treated mutants (Fig 6A). This confirms thatwww.embomolmed.org EMBO Mol Med 4, 1–14rapamycin blocked mTOR signalling without influencing the
upstream protein kinase AKT.
The loss of Pten from Schwann cells recruits more axons for
myelination (Goebbels et al, 2010). Accordingly, when
quantified at P43, placebo-treated Pten mutant sciatic nerves
harboured significantly more myelinated axons than control
nerves (4289 90.99 in mutants vs. 3684 159.8 in controls).
Since this increase in the number of myelinated axons was not
lowered by the administration of rapamycin (4240 116.5 in
treated mutants vs. 3721 103.2 in treated controls; Fig 6B) we
conclude that at the onset of treatment the number of myelin
profiles in the mutants is already set.
Myelinated axons were found more loosely spaced in
(placebo-treated) Pten mutants than in wildtype controls
(2.512 0.16 axons/100mm2 in mutants vs. 4.044 0.183
axons/100mm2 in controls). Consequently, in rapamycin-
treated mutants myelinated axons were more densely packed
than those in placebo-treated mutants (3.465 0.111 axons/
100mm2 in treated mutants; Fig 6C). In wildtype controls
rapamycin had no obvious effect on the density of myelinated
axons.
To assess the effect of rapamycin on myelin pathology we
quantified tomacula, comma-like outfoldings, and evaginating
recurrent loops in sciatic nerve cross sections of rapamycin and
placebo-treated mutants and their respective wildtype controls
(hereafter referred to as mutants(þRap), mutants(Rap), con-
trols(þRap) and controls(Rap), respectively). As expected, the
number of myelin abnormalities was significantly higher in
mutants(Rap) than in controls(Rap) (Fig 6D–F). After 30 days of
treatment, tomacula were reduced by 74% in mutants(þRap)
(52 12.87 per cross section) compared to mutants(Rap)
(209 20.76) (Fig 6D). Similarly, recurrent loops were reduced
by 75% (17.88 3.393 in mutants(þRap) vs. 72.17 7.897 2012 EMBO Molecular Medicine 5
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Figure 4. Enhanced AKT activity and unaltered expression levels of Dlg1
and Par-3.
A. Immunostaining of sciatic nerve cross sections with antibodies against p-
AKT (in red) and MPZ as a marker of compact myelin (in green). Scalebar,
10mm.
B. Teased sciatic nerve fibres stained with antibodies against p-AKT (in red)
and MAG as a marker of non-compact myelin (in green). Scale bars, 50mm.
C. Costaining of MAG and Dlg1 (upper panels) and MAG and Par-3 (lower
panels). Dlg1 and Par-3 are similarly enriched in mutants and controls in
regions of non-compact myelin. Scale bar, 50mm.
Table 1. Reduced NCV and CMAP amplitudes in Pten mutant mice
Controls Mutants
CMAP amplitudes (mV)
Proximal stimulation 19.8 (2.7) 5.3 (2.4)a
Distal stimulation 21.8 (2.2) 7.4 (2.7)b
Motor NCV (m/s) 26.7 (3.8) 17.7 (3.7)c
Motor latency (ms)
Proximal stimulation 2.1 (0.1) 2.4 (0.2)
Distal stimulation 1.3 (0.1) 1.4 (0.1)
F-wave latency (ms)
Proximal stimulation 4.7 (1.1) 6.2 (0.8)
Distal stimulation 6.2 (0.5) 7.1 (0.7)
Electrophysiological recordings are from P43 old mutant (Ptenflox/floxCnpCre/þ)
and age matched control (Ptenflox/floxCnpþ/þ) mice. All data are expressed as
mean SEM. Sample size is n¼3 per genotype. Differences between controls




6mutants(Rap); Fig 6E). Finally, also comma-like outfoldings
were reduced by 49% (60.13 13.37 in mutants(þRap) vs.
117.2 6.882 in mutants(Rap); Fig 6F). Rapamycin treatment
did not change the myelin profile in control mice. Taken
together, these results demonstrate that enhanced mTOR
downstream signalling contributes to the myelin pathology of
Pten mutant mice.
Focal hypermyelination after inactivation of Pten in Schwann
cells of adult mice
To determine whether changes in phosphoinositide metabolism
would also cause neuropathy with focally folded myelin after
development has completed, we inactivated the floxed Pten
gene in adult mice by tamoxifen (TM) induced Cre recombina-
tion. We intercrossed Ptenflox/flox mice to a TM inducible Plp-
CreERT2 driver line (Leone et al, 2003). Two month-old double 2012 EMBO Molecular Medicinetransgenics (Ptenflox/floxPlp-CreERT2) and Ptenflox/flox controls
received intraperitoneal TM injections for 10 consecutive days,
and were analysed histologically 3.5 months later. Indeed,
all previously documented myelin abnormalities, including
comma-shaped outfoldings, recurrent loops and tomacula were
also found in these double transgenic mice (Fig 7A and B), albeit
to a lesser extent. This demonstrates that PtdIns(3,4,5)P3 levels
must be regulated by PTEN also in adult Schwann cells in order
to maintain the integrity of the mature myelin sheath.DISCUSSION
We have shown that the ablation of the lipid phosphatase gene
Pten in Schwann cells leads to a progressive peripheral
neuropathy in mice that resembles features of certain human
forms of CMT diseases, such as CMT4B1 and HNPP, which are
genetically unrelated. In this novel disease model, the focal
forms of exuberant myelin growth were documented at the EM
level as myelin outfoldings, recurrent loops and tomacula. At
the physiological level, they are associated with a diffuse
slowing of conduction velocity. Although the number of
myelinated axons was not diminished, CMAP amlitudes were
reduced after both proximal and distal stimulation suggesting
failures in axonal conduction. However, we do not consider
PTEN an inherited neuropathy disease gene. In mice, Pten nullEMBO Mol Med 4, 1–14 www.embomolmed.org
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Figure 5. Reduced NCV and CMAP.
A. Representative traces of sciatic nerve CMAPs recorded from a foot muscle after proximal and distal stimulation. Arrows indicate the stimulus and the onset
of the CMAP. Asterisk marks the F-wave latency. Compared to controls, Pten mutants display prolonged latencies and decreased CMAP amplitudes.
B–D. Motor nerve conduction studies of 43 days old controls and mutants (n¼3 per group). Mutants show significantly reduced CMAP amplitudes after (B) distal
and (C) proximal stimulation. (D) Sciatic NCV is significantly slowed in Pten mutants compared to controls. Error bars represent the SEM. p values were
calculated by two-tailed Student’s t-test.mutants are not viable (Di Cristofano et al, 1998), and human
(heterozygous) germline mutations cause a rare PTEN auto-
somal-dominant harmatoma syndrome (Hobert & Eng, 2009)
comprising four major clinically distinct syndromes with only
anecdotal reports of neuropathy in Cowden disease (Waite &
Eng, 2002).
In Pten-mutant mice, the focal hypermyelination is a cell
autonomous defect of myelinating Schwann cells. Cnp-Cremice
(Lappe-Siefke et al, 2003) recombine target genes early in the
Schwann cell lineage (Goebbels et al, 2010). While we cannot
rule out the occasional deletion of Pten in common precursor
cells of Schwann cells and DRG neurons (or oligodendrocytes
and spinal motor neurons; Genoud et al, 2002), the reportedwww.embomolmed.org EMBO Mol Med 4, 1–14phenotype is unlikely to be caused by abnormal behaviour of a
fewmutant neurons. Cell autonomy is also supported by a similar
phenotype in combination with the Plp-CreERT2 transgene and
tamoxifen treatment of adult mice, which does not lead to
recombination in (embryonic) neuron–glia progenitors.
Central nervous system (CNS) axons and small calibre axons
in the peripheral nervous system (PNS) are morphologically
hypermyelinated in Pten mutant mice, as evidenced by
decreased g-ratios (Goebbels et al, 2010). However, our mutants
differ markedly from mice that overexpress NRG1 type III in
neurons and are uniformly hypermyelinated (Michailov et al,
2004) because they exhibit an unusual degree of focal
hypermyelination in the PNS. Thus, the absence of PTEN 2012 EMBO Molecular Medicine 7
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Figure 6. Rapamycin treatment ameliorates myelin pathology in Pten mutants.
A. Westernblots of sciatic nerve lysates from mutant mice treated with placebo (Rap) or rapamycin (þRap) from P13 to P43. Rapamycin treatment
substantially reduced downstream phosphorylation of S6 but did not lower total protein levels of S6 or levels of P-AKT when compared to Actin as a loading
control.
B–F. When quantified on semithin cross sections, the total number of myelinated axons was invariably higher in mutants than in controls and not influenced by
rapamycin treatment (B). While the density of myelinated axons was reduced in mutants(Rap) when compared to controls(Rap), rapamycin treatment
significantly restored the axonal density in mutants(þRap) closer to control levels (C). Rapamycin treatment also significantly lowered the number of tomacula
(D), recurrent loops (E) and outfoldings (F) in the mutants(þRap) when compared to mutants(Rap). Controls(Rap), n¼8; controls(þRap), n¼6; mutants(Rap),
n¼ 6; and mutants(þRap), n¼ 8. Error bars represent the SEM. p values were calculated by two-tailed Student’s t-test.
8(and enhanced PI3K downstream signalling) is not simply a
phenocopy of enhanced NRG1/ErbB signalling in Schwann cells
(Michailov et al, 2004; Taveggia et al, 2005). This conclusion is
in agreement with recent studies revealing a role of ERK1/2
kinase in mediating NRG1/ErbB signalling in Schwann cells
(Newbern & Birchmeier, 2010; Newbern et al, 2011). However, 2012 EMBO Molecular Medicinethe elevated levels of PtdIns(3,4,5)P3 in Pten mutant Schwann
cells were clearly associated with a focally hypermyelinating
phenotype that was significantly ameliorated by the treatment of
mice with rapamycin. The latter suggests that downstream of
PI3K/AKT, the rapamycin-sensitive mTOR complex 1
(mTORC1, including mTOR and Raptor) not only promotesEMBO Mol Med 4, 1–14 www.embomolmed.org
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Figure 7. Myelin pathology after inactivation of
Pten in adult mice.
A. Semithin sections of a control mouse (Ptenflox/flox)
and a double transgenic mutant mouse har-
bouring a Plp-CreERT2 transgene (Ptenflox/floxPlp-
CreERT2). Mice were treated with TM at 2 months
of age and analysed 3.5 months later. Outfoldings
(arrows) and tomacula (arrowhead) also occur
after ablation of Pten in adult mice. Scale bar,
20mm.
B. Ultrastructural analysis of myelin pathology after
adult inactivation of Pten with comma-shaped
outfoldings (left panel), recurrent loops (middle
panel) and tomacula (right panel). Scale bars,
1mm.protein translation and regulates cell size (Weichhart, 2012), but
also plays a critical role in the formation of excessive myelin
growth in the PNS, similar to its role in the CNS (Narayanan
et al, 2009). These data also identify a possible target for the
treatment of tomaculous neuropathies.
Implications for normal myelin growth
Judged from the earliest disease stages, the myelin pathology in
Pten conditional mouse mutants appears to originate from small
regions of non-compacted myelin membranes, i.e. paranodal
loops and Schmidt–Lantermann incisures. The same sites
contain high levels of phosphorylated AKT kinase. It is likely
that this staining identifies a subcellular region of myelinating
Schwann cells, in which PTEN is normally localized and
antagonizes PI3 Kinase signalling, myelin growth and mem-
brane turnover of the mature nerve. This function is required
throughout life, as evidenced by similar myelin outfoldings and
tomacula also in the nerves of adult mice, in which Cre
recombination was induced by tamoxifen. Our findings are also
in agreement with the model of PTEN as an inhibitor of
myelination (Goebbels et al, 2010), which, in conjunction with
the scaffolding protein Dlg1, serves as a break to prevent
‘overmyelination’ in the PNS (Cotter et al, 2010). We note that
the carboxy-terminal PDZ (‘postsynaptic density 95; discs large;
zonula occludens 10) binding motif of PTEN may not only
interact with the stabilizing Dlg1 to regulate myelin formation.
The PDZ binding motif of PTEN can also interact with PDZ
domains of other resident scaffolding proteins that are present in
Schwann cells, notably MAGI-2 and Par-3 (Feng et al, 2008; von
Stein et al, 2005; Wu et al, 2000), both of which reside in non-
compact myelin (Poliak et al, 2002). During normal Schwannwww.embomolmed.org EMBO Mol Med 4, 1–14cell development, Par3 is essential for establishing an
intracellular polarity against the axon and thus for myelination
(Chan et al, 2006). It is possible that at later stages Par3 recruits
PTEN also to non-compact myelin where PtdIns(4,5)P2 and
PtdIns(3,4,5)P3 levels have to be locally controlled. Also the
periaxin gene encodes proteins with PDZ domains, L-periaxin
and S-periaxin (Dytrych et al, 1998). These are expressed in
Schwann cells and may play a role in the stabilization of the
myelin sheath (Scherer et al, 1995). Given, that mutations of the
human PRX gene and Prx null mutations in mice cause
neuropathy with hypermyelination and focal myelin sheath
thickening (Gillespie et al, 2000; Takashima et al, 2002), it is
tempting to speculate that also the PDZ domain of periaxin may
bind to and recruit PTEN.
A two-step model of myelin growth and pathology
Inhibiting mTORC1 with rapamycin in mice blocked patholo-
gical myelin outgrowth but had no obvious effect on wildtype
Schwann cells. It is possible that the treatment effect, starting at
age P13, when PNSmyelination is already quite advanced, came
simply too late to affect myelin formation in the wildtype.
Alternatively, PTEN itself is the most rate-limiting regulator of
developmental myelination, physically associated with mem-
brane compartments that are thought to incorporate new
membrane material (O¨zc¸elik et al, 2010). We propose that
regions such as SLI and paranodal loops (in wildtype mice) are
‘protected’ by the presence of PTEN and only limited
incorporation of newly synthesized myelin membranes takes
place. This local PTEN ‘brake’ would function independently of
regulated (mTORC1-dependent) cell growth and bulk mem-
brane synthesis. 2012 EMBO Molecular Medicine 9
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10In contrast, in PTEN-deficient Schwann cells there is not only
enhanced (mTORC1-dependent) synthesis of membranes, but
also uncontrolled incorporation of these membranes into the
myelin growth zones, constituting ‘redundant’ myelin. This
may explain why blocking mTORC1 reduces the formation of
tomacula and myelin outfoldings in PTEN mutants, but not
myelination under physiological conditions. This model can
also explain why the mere overexpression of constitutively
active Akt (DDAkt) is by itself not efficient in inducing de novo
myelination by Schwann cells or tomacula (Flores et al, 2008).
Themodel is also in agreement with our finding that the number
of myelin outfoldings (i.e. the ‘primary’ pathology) was less
affected by rapamycin treatment than the number of tomacula
found in sciatic nerve cross sections of Pten mutant mice. Here,
we propose that the outfoldings as primary abnormalities are
most likely caused by an altered (phosphoinositide-dependent)
cytoskeletal rearrangement and altered membrane dynamics in
mutant Schwann cells due to the loss of PTEN as the local
‘brake’, whereas the activation of AKT and mTORC1 in
Schwann cells contributes to bulk membrane growth, and thus
mostly to the size of focal myelin abnormalities resulting
eventually in the formation of tomacula.
We note that for epithelial cells a heterogeneous and
polarized lipid composition has been reported with
PtdIns(3,4,5)P3 (along with its synthesizing enzyme PI3K)
being enriched in the basolateral membrane (Gassama-Diagne
et al, 2006). In contrast, PtdIns(4,5)P2 (along with PTEN)
resides mostly in the apical domain (Martin-Belmonte et al,
2007). Epithelial cells and myelinating Schwann cell may be
polarized in a similar way (O¨zc¸elik et al, 2010; Pereira et al,
2012), such that the outer abaxonal Schwann cell membrane
containing PI3K and PtdIns(3,4,5)P3 represents the ‘basolateral-
like’ domain, while the inner adaxonal domain and the
Schmidt–Lanterman incisures are enriched in PtdIns(4,5)P2
and PTEN and represent an ‘apical-like’ domain. Interestingly,
when PtdIns(3,4,5)P3 is ectopically inserted into the apical
membrane of epithelial cells, these form membrane protrusions
from the apical surface, which contain basolateral plasmamem-
brane proteins (Gassama-Diagne et al, 2006) and are enriched in
filamentous actin. This is compatible with the idea that elevated
PtdIns(3,4,5)P3 (in the absence of inhibitory PTEN) in the
‘apical-like’ Schwann cell compartment triggers pathological
membrane deposition and myelin outfoldings.
Thus, we suggest a two-step model of myelin pathology for
Pten-mutant mice: (i) abnormal PtdIns(3,4,5)P3 levels perturb
the polarization of non-compact myelin membranes and cause
focal, e.g. actin-dependent membrane protrusions, which is
followed by (ii) enhanced AKT/mTORC1-signalling that con-
tributes to uncontrolled membrane growth at these sites.
Why would elevated PtdIns(3,4,5)P3 in the ‘apical-like’
domain of a Schwann cell affect polarity, motility and
membrane dynamics? Since actin nucleation is an important
driving force of Schwann cell membrane movements (Fernan-
dez-Valle et al, 1997) it is plausible that abnormally high
PtdIns(3,4,5)P3 levels induce pathology by recruiting pleck-
strin-homology (PH) domain containing regulatory proteins
(such as GEFs and GAPs) as activators of small RhoGTPases and 2012 EMBO Molecular Medicinethe actin cytoskeleton (Saarikangas et al, 2010). We note that
GEFs, RhoGTPases and the downstream effector protein N-
WASP (neural Wiskott–Aldrich syndrome protein) take part in
normal myelin biogenesis (Benninger et al, 2007; Feltri et al,
2008; Nodari et al, 2007; Novak et al, 2011), and that loss of
Frabin/FGD4 (a GEF protein with FYFE and PH domains)
underlies demyelination in patients with CMT neuropathy type
4H (Stendel et al, 2007). We also note that the mTORC2 protein
complex (which includes mTOR and Rictor) influences the
dynamics of the actin cytoskeleton and is largely resistant to
rapamycin (Weichhart, 2012).
Clinical implications
Tomacula, outfoldings and focal thickenings of the myelin
sheath have been found in many peripheral neuropathies,
including different forms CMT, HNPP, chronic inflammatory
demyelinating neuropathy, paraproteinemic neuropathy, as
well as in different animal models of peripheral nerve disorders
(Sander et al, 2000). This suggests that a ‘final common
pathway’ is precipitated by very different aetiologies, but how
these tomacula are formed is not known. Abnormal phosphoi-
nositide signalling emerges as a feature of severe neuropathies
with focally pronounced myelin overgrowth, involving disease
genes, such as in CMT4B1 (Mtmr2), CMT4B2 (Mtmr13) and
CMT4H (Frabin/FGD4) that encode phosphoinositide binding
FYFE and PH domains (Suter, 2007).
In conditional MTMR2 null mutant mice, the scaffolding
protein Dlg1, which is by itself required for myelination (Bolis
et al, 2009), has lost its normal abundance on the paranodal
regions of Schwann cells (Bolino et al, 2004). Since PTEN is
directly recruited by Dlg1 (Cotter et al, 2010), we hypothesize
that a local secondary loss of PTEN could be part of the disease
mechanism that underlies myelin outfoldings in CMT4B1
neuropathy.
Because phosphorylated AKT is an indicator of enhanced
PI(3,4,5)P3 signalling, which underlies myelin outfoldings in
Ptenmutant mice, it could also be a molecular signature of other
tomaculous neuropathies. However, little is known about the
levels of pAKT in myelin (outfoldings) of these patients.
Nevertheless, our data in mice suggest that AKT/mTORC1
signalling is important to drive the abnormal myelin growth.
This identifies mTOR as a possible pharmacological target for
therapy, independent of the steady-state level of pAKT and the
rate of (pathological) myelin growth. Although systemic
rapamycin would never be an option for the treatment of a
peripheral neuropathy in man, the local (e.g. transdermal)
administration of rapamycin analogs (Rauktys et al, 2008) can
be explored for the treatment of specific aspects (e.g.
neuropathic pain), using the available animal models.MATERIALS AND METHODS
Mice
All experiments were performed according to the Lower Saxony State
regulations for animal experimentation in Germany. Ptenflox/flox and
PLP-CreERT2 mice were genotyped as described (Leone et al, 2003;EMBO Mol Med 4, 1–14 www.embomolmed.org
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The paper explained
PROBLEM:
Like the insulation of an electric cable, myelin membranes
insulate nerve cell processes (axons), which allows the rapid
propagation of nerve impulses. In the peripheral nervous system,
these myelin membranes are made by Schwann cells. Genetic
defects of peripheral myelination often block axon function and
cause muscle weakness. A prominent neuropathological feature
of several inherited neuropathies, including hereditary neuro-
pathy with liability to pressure palsies (HNPP) and Charcot-
Marie-Tooth disease type 4B1 (CMT4B1) are ‘tomacula’ or other
forms of focally folded myelin. Despite major progress in defining
the genetic cause of myelin diseases, the molecular mechanisms
that result in abnormal myelin outgrowth in some forms of CMT,
but not in others, have remained obscure.
RESULTS:
We have hypothesized that tomacula result from an uncontrolled
local synthesis of myelin membranes, which is normally under
control of specific growth factor receptors (neuregulin-1/ErbB2
as well as downstream PI3 Kinase and/or MAPK signalling). To
test whether enhanced PI3K signalling [i.e. elevated phospha-
tidylinositol(3,4,5) trisphosphate levels activating the serine/
threonine protein kinase AKT] would be sufficient to cause a
tomaculous neuropathy, we generated mice, which lack PTEN (a
lipid phosphatase antagonizing PI3K activity) selectively in
Schwann cells. Indeed, this genetic modification was sufficient to
cause focal hypermyelination, myelin outfoldings, and tomacula,
even when induced in adult animals, i.e. after myelination is
completed. This striking pathology is also dependent on active
mTOR kinase, because the disease is significantly ameliorated in
mice treated with the mTOR antagonist rapamycin.
IMPACT:
We suggest a model in which certain, non-compact regions of the
myelin sheath are under lifelong ‘protection’ by PTEN, preventing
abnormal membrane outgrowth. Furthermore, our data indicate
that mTOR signalling is important to drive abnormal myelin growth,
which identifies this serine/threonine protein kinase as a possible
pharmacological target for the therapy of tomaculous neuropathies.Lesche et al, 2002). Cnp-Cre mice were genotyped with primers
Cnp-E3s, 50-GCC TTC AAA CTG TCC ATC TC-30 Cnp-E3as, 50-CCC AGC
CCT TTT ATT ACC AC-30 and puro3, 50-CAT AGC CTG AAG AAC GAG A-30 .
Genomic DNA for PCR analysis was isolated from tail biopsies using
Invisorb Spin Tissue Mini Kit (Invitek) according to the manufacturer’s
directions.
Rapamycin and tamoxifen treatment
Rapamycin (LC Laboratories) was dissolved in vehicle solution contain-
ing 5% polyethyleneglycol 400, 5% Tween 80 and 4% ethyl alcohol.
Rapamycin or placebo (vehicle solution) was administered by
intraperitoneal injections at 5mg/kg for 5 days a week from postnatal
day (P) 13–43. Tamoxifen (TM; Sigma) was dissolved in sunflower oil/
ethanol (10:1) to a final concentration of 10mg/ml. Two month-old
mice received intraperitoneal injections at 100mg TM per gram mouse
weight once a day for 10 consecutive days and were analysed 3 months
later. As carrier control sunflower oil/ethanol (10:1) was injected.
Protein analysis
Sciatic nerve lysates were homogenized in 1ml of lysis-buffer (50mM
HEPES, pH 7.5, 150mM NaCl, 1.5mM MgCl2, 5mM EGTA, 10%
glycerol, 1% triton X-100, 2mM Na3VO4) and protease inhibitors
(Complete tablets, Roche, Basel, Switzerland) using an Ultraturrax (T8,
Ika, Staufen, Germany) at highest settings (30–60 s). After incubation
for 15min on ice insoluble material was removed by centrifugation at
16.000 g, 48C for 15min. For Westernblot analysis, 40mg of protein
lysate was size-separated on 12% of SDS-polyacrylamide gels and
blotted onto PVDF membranes (HybondTM-P, Amersham Biosciences,
UK) by Bio-Rad western blotting method. Membranes were blocked in
5% milk powder (in PBS) for 1 h at room temperature. Primarywww.embomolmed.org EMBO Mol Med 4, 1–14antibodies directed against p-AKT (mRb, 1:1000; Cell Signaling), AKT
(mRb, 1:1000; Cell Signaling), p-ERK (mRb, 1:1000; Cell Signaling);
ERK (mRb, 1:1000; Cell Signaling), p-mTOR (mRb, 1:250; Cell
Signaling), PTEN (mRb, 1:1000; Cell Signaling); p-S6 (mRb, 1:1000;
Cell Signaling), and S6 (mRb, 1:1000; Cell Signaling) were diluted in
blocking buffer and incubated overnight at 48C. Membranes were
washed 310min in TBS-T buffer (50mM Tris-HCl, pH 7.4, 150mM
NaCl and 0.05% Tween-20), followed by an incubation with horse-
radish peroxidase-conjugated secondary antibodies (1:5000, Jackson
ImmunoResearch, West Grove, PA). After four more washes with TBS-T
buffer, immunoreactive proteins were detected with an enhanced
chemiluminescence kit (Western LightningTM, Westernblot Chemilu-
minescence Reagent Plus, PerkinElmer Life Sciences, Waltham, MA)
according to the manufacturer’s instructions.
Electron microscopy
For electron microscopy mice were anaesthetized with avertin
(Sigma–Aldrich, St.Louis, MO) and perfused with 15ml of Hanks
balanced salt solution (HBSS, PAA laboratories, Pasching, Austria)
followed by fixative (4% PFAþ0.1M Phosphate bufferþ0.5%
NaClþ2.5% glutaraldehyde). Sciatic nerves were dissected at the
level where the nerve exits the greater sciatic foramen. Nerves were
contrasted with 1% osmium tetraoxide and embedded in epoxy resin.
Semi-thin (0.5mm) and ultra-thin (50–60nm) sections were cut,
using a microtome (RM 2155, Leica Microsystems, Wetzlar, Germany)
with a diamond knife (Histo HI 4317, Diatome, Biel, Switzerland).
Semithin sections were stained with azur-II-methylenblue for 1min at
608C. Light microscopic observation was performed using a Leica DM
RXA microscope and a video frame grabber (ProgRes C14, Jenoptic,
Jena, Germany). Images were digitalized with Openlab software 2012 EMBO Molecular Medicine 11
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12(Improvision, Coventry, UK). Ultra-thin sections were stained with 2%
uranylacetate (30min) and 1% lead citrate solution (12min) and
analysed using a LEO EM912AB electron microscope (Carl Zeiss NTS,
Oberkochen, Germany). Pictures were taken with an on-axis
20482048 CCD camera (Proscan, Scheuring, Germany).
Histology and immunostaining
For immunohistochemistry mice were anaesthetized with Avertin and
perfused with 15ml of Hanks balanced salt solution, followed by
50ml of 4% paraformaldehyde in PBS. Sciatic nerves were dissected
and postfixed for 30min at 48C following embedding in paraffin and
cutting in 5mm slices (Microm HM400, Walldorf, Germany). Teased
fibre preparations of sciatic nerves were performed immediately after
perfusion and post fixation for 30min on 48C. The connective tissue
was stripped off and nerves were separated into single fibres using a
fine needle and a forceps and dried on an object slide. Slides
containing paraffin sections or teased fibre preparations were
incubated overnight with primary antibodies directed against MPZ
(mM, 1:1000; provided by J. Archelos, University of Graz, Austria), p-
AKT (pRb, 1:50; Cell Signaling), MAG (mM, 1:200; Chemicon), Dlg1
(pRb, 1:200; provided by A. Bolino, Dulbecco Telethon Institute, Milan,
Italy) and Par-3 (pRb, 1:200; provided T. Pawson, Samuel Lunenfeld
Research Institute, Toronto, Canada). After washing, slides were
incubated with corresponding secondary Cy2 (1:100, Jackson Im-
munoResearch) and Cy3 (1:1000, Jackson ImmunoResearch) con-
jugated antibodies for 1 h at room temperature. Sections were
mounted with AquaPolymount (Polysciences, Warrington, PA). For
analysis of myelin abnormalities, teased fibres were osmicated with
2% osmium tetraoxide for 5 h following dehydration in ethanol series.
For depiction of Schmidt–Lanterman incisures postfixed sciatic nerves
were osmicated and dehydrated in ethanol series before teasing. Slides
were coverslipped with epoxy resin. Digital images were obtained by
using a Zeiss Axiophot microscope, a Leica DM RXA microscope, and a
LSM5 Zeiss confocal laser-scanning microscope. Image processing was
performed with Openlab 2.2.3. (Improvision), Photoshop CS3 and
Illustrator CS2 software (Adobe Systems, San Jose, CA).
Morphometry
Digitized, overlapping pictures (magnification 100) of semithin
sciatic nerve cross sections were fused to a continuous picture of a
whole sciatic-nerve cross-section by using Photoshop CS (Adobe
systems, San Jose, CA). Pictures were used to determine the numbers of
myelinated axons, myelin abnormalities and g-ratios (100 randomly
chosen fibres per nerve cross-section). G-ratios were determined by
dividing the diameter of an axon by the diameter of the same axon
including the myelin sheath. Fibres with myelin abnormalities in the
plane of section were excluded. When not stated differently,
measurements were performed from 3 age- and sex-matched mice
per genotype and age. We implemented a plugin for the ImageJ
software (http://rsb.info.nhi.gov/imagej, version 1.37), which allowed
for semi-automated analysis of randomly selected sets of fibres. Plugin
and source code are available online (http://gratio.efil.de).
Electrophysiology
Electrophysiology was performed on sciatic nerves of mice at 43 days
of age. Mice were anaesthetized with Ketaminhydrochloride/Xylazin-
hydrochloride (100mg/kg BW/8mg/kg BW). A pair of steel needle 2012 EMBO Molecular Medicineelectrodes (Schuler Medizintechnik, Freiburg, Germany) was placed
subcutaneously along the nerve at sciatic notch (proximal stimula-
tion). A second pair of electrodes was placed along the tibial nerve
above the ankle (distal stimulation). Supramaximal square wave
pulses lasting 100ms were delivered using a Toennies Neuroscreen1
(Jaeger, Hoechsberg, Germany). CMAP was recorded from the intrinsic
foot muscles using steel electrodes. Both amplitudes and latencies of
CMAP were determined. In addition, we measured the latency of late
potentials resulting from the backfiring of antidromically activated
motoneurons (F-waves). The distance between the two sites of
stimulation was measured alongside the skin surface with fully
extended legs and NCVs were calculated automatically from sciatic
nerve latency measurements.
Statistical analaysis
Statistical analysis was performed by using two-tailed Student’s t-test
and the programs GraphPad Prism v4.03 (GraphPad, San Diego,
CA, USA) and Microsoft Excel 2003. Results are expressed as
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